A report from the 23rd European Academy of Dermatology and Venereology Congress (October 8-12 - Amsterdam, The Netherlands).
The 23rd Congress of the European Academy of Dermatology and Venereology started in Amsterdam with a day dedicated mostly to courses, during which electronic posters were also available. Scientists and researchers attending the conference had an opportunity for reviewing the latter investigations in dermatology through a series of computer terminals showing posters and allowing for e-mail discussions with the presenters. In a number of presentations, psoriasis was one of the major focuses of interest during EADV. New clinical research with emerging biologics and studies to validate the bioequivalence of biosimilars versus their originator monoclonal antibodies centered the scientific attractions towards which researchers and clinicians attending the conference were drawn. However, among the electronic posters at the conference, the results of initial clinical trials with a number of potential new therapies for other skin conditions were also presented. While shying away from psoriasis, a "late-breaking news in dermatology" session, wherein the results of clinical trials with innovative therapies for cutaneous diseases were reported, included large trials with established drugs aiming at novel indications, as well as first-in-human trials to validate the potential of investigational drugs. This and additional information and data reported during the conference and related with treatment for skin and skin structure diseases are summarized in the following report.
Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
X
X
Rabasseda
D000818:Animals; D003880:Dermatology; D006801:Humans; D012871:Skin Diseases / Q000188:drug therapy*; D014686:Venereology
Atopic dermatitis; Cutaneous malignancies; Dermatology; Psoriasis; Skin infections